Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, I get it, lots of goodwill but selling at cost, correct?
Based on what?
Yes, in prep for commercialization of 180 day in US and to fund the 1 year sensor to approval.
I doubt it goes down to the offering price. But if it does, I load up.
Perfect time to do it if it had to be done. Stock will absorb it and continue up after a cool off.
I will and I will add. This is just the beginning.
Congrats all Longs! Now let’s see if another player comes in higher before the deal closes later this year.
UnitedHealth/Optum tends to be a late adopter in contracting for new meds and devices. They want to see how a new product is being used across the market before negotiating a contract.
Just a matter of time until UnitedHealth agrees to coverage. These tend to all fall in place once a couple big boys provide coverage.
No offense Rico a, but you do realize that they relaunched a US sales force in partnership with Ascensia? They understood that they didn’t have the know how to drive sales alone. This is in very good hands from a sales perspective.
“Strong fourth quarter performance was driven by sales in Europe and supported by Ascensia’s initial US sales.”
Uhhhhhhhh.....
News?
An article from a year and a half ago? Really?
It’s back on baby!
What’s with sp yesterday and so far today? Any news?
3-4 weeks, I wouldn’t worry about it
Good call!
They got it!
FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease
U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)
NEWS PROVIDED BY
U.S. Food and Drug Administration
Jul 31, 2020, 21:06 ET
SILVER SPRING, Md., July 31, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). This is the only FDA-approved drug that contains a purified drug substance derived from cannabis. It is also the second FDA approval of a drug for the treatment of seizures associated with TSC.
Thoughts from anyone on the articles going around from researchers stating research needs to be done immediately on CBD effects on treating lungs of COVID patients? Several articles making the rounds over last two weeks and I would guess has had impact on the SP.
The only company with current trials in THCV is GWPH. Once again, they are ahead of everyone in this space
It’s great, but why did it happen in the last 2 days? I don’t see any updates news.
We can agree to disagree.
So let’s see. Beats estimates and is thissss close to being profitable. If 2nd quarter is flat as was stated on the earnings call, and assuming most commercial expenditures are drastically reduced for all of Q2 (at least in the US), then I expect the company becomes profitable in Q2.
Next, drug was descheduled at a federal level, waiting on states to follow and payers will likely lessen coverage restrictions at the very least with refills.
Next TSC approval by end of July “effectively doubling patient popultation” for approved indications.
Next Sativex is a pipeline in a drug, but sounds like trial enrollment is delayed until 2nd half 2020. Fine.
Sure there will be volatility over next several months due to world events, but damn, this is a great long term hold with an eventual buy out.
GLTA
Hey, remember when this was about to launch and the VP of Market Access, M. Masterson, was considered to be “the most innovative person in Market Access?” LOLOLOLOLOL
Excellent news, this will further remove restrictions to dispensing the drug.
There’s already 6-9 months of supply in the US already and the Supply chain has not yet been impacted. Biggest impact will be the launch in Europe.
Wow, nice swing and miss.
No thanks, at least not yet. Maybe at $2. I’m not catching a falling knife right now.
They already announced these results in Jan, did you think they would change?
Great, but GWPH isn’t a marijuana stock. Maybe post on this on Aurora, Tilray etc message boards?
Do your homework. Ave cost per patient is around $30k a year. Average copay is probably about $50-$60 a month. Out of pocket for BS OTC CBD is about $300-$400 a month. It’s what insurance is for, to help pay for drugs.
Ah, two folks pointed out I said “the average investor is d you m bee.
That’s kind of questionable. I didn’t call anybody out. More a generic statement but oh well.
Close to $300 mil in year one sales when wall street forecast was what $125 mil? This will move up hard in 2020. Europe takes off, TSC in the US, this is a gift.
What an over reaction. On pace for $290 mil net sales in year 1 when a year ago analysts forecasted first year sales of what $125 mil?
TSC submitting one Jan with expected approval by mid 2020.
Europe launch in full swing beginning 2020.
Sativex sounds like potential approval in early to mid 2021.
Schizo and autism moving forward.
Total Epidiolex sales of maybe $500+mil in 2020? (Probably conservative).
I must be missing something bc it seems like all good news to me.
No asbestos found after 48 new independent lab test on the same bottle previously tested.
LOLOLOLOL!!!
At $130k a year, this extended release of an ages old drug prices itself out of any success.
Who the hell came up with the price?!? Hopefully the we’re terminated.
You’ve lost even more than I, congrats. I understand that NEJM is not an “oncology” journal. It’s also not a “cannabis” journal, but it published 2 peer reviewed articles on GW’s Epidiolex bc it was a breakthrough medication for Epilepsy. If ONCS has a true breakthrough of that caliber it will be in NEJM or Lancet Oncology at the very least.
This news and article are very nice as was the recent partnership, but as evidenced by the SP, “nice” info won’t move this.
I remain invested and even pinched some more at $1.81 to avg down.
The future is much brighter to me now than it was 6 months ago, but ONCS is still waiting in that true “breakthrough” to send this through the roof.
We’ll see.
It’s totally relevant and being in one of the prestige journals will bring a level of credibility that ONCS has yet to receive. This is coming from a long term holder since 2013.
This is all great news, but won’t affect SP yet, as evidenced by today.
This will matter more when data is published in a “peer reviewed” Journal like NEJM.